154 related articles for article (PubMed ID: 10899364)
1. Further characterization of the discriminative stimulus effects of spiradoline.
Holtzman SG
Pharmacol Biochem Behav; 2000 Jul; 66(3):517-22. PubMed ID: 10899364
[TBL] [Abstract][Full Text] [Related]
2. Discriminative stimulus effects of spiradoline, a kappa-opioid agonist.
Holtzman SG; Cook L; Steinfels GF
Psychopharmacology (Berl); 1991; 105(4):447-52. PubMed ID: 1663252
[TBL] [Abstract][Full Text] [Related]
3. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.
Carey GJ; Bergman J
J Pharmacol Exp Ther; 2001 Apr; 297(1):215-23. PubMed ID: 11259547
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of the discriminative stimulus effects of the kappa-opioid agonist spiradoline.
Holtzman SG; Steinfels GF
Psychopharmacology (Berl); 1994 Nov; 116(3):243-8. PubMed ID: 7892412
[TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
Picker MJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Pitts RC; Dykstra LA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1501-8. PubMed ID: 7996463
[TBL] [Abstract][Full Text] [Related]
8. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey.
White DA; Holtzman SG
Psychopharmacology (Berl); 2003 May; 167(2):203-10. PubMed ID: 12644889
[TBL] [Abstract][Full Text] [Related]
11. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids.
Zhang L; Walker EA; Sutherland J; Young AM
Psychopharmacology (Berl); 2000 Feb; 148(2):136-45. PubMed ID: 10663428
[TBL] [Abstract][Full Text] [Related]
13. Assessing spiradoline-like discriminative effects of DuP 747: influence of route of administration.
Holtzman SG; Steinfels GF; Schmidt WK
Pharmacol Biochem Behav; 1994 Mar; 47(3):487-91. PubMed ID: 8208766
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys.
Powell KR; Holtzman SG
Pharmacol Biochem Behav; 2000 Jan; 65(1):43-51. PubMed ID: 10638635
[TBL] [Abstract][Full Text] [Related]
15. Enhanced sensitivity to the antinociceptive effects of kappa opioids in naltrexone-treated rats: dose- and time-dependent effects.
Smith MA; McClean JM; Greene JL
Behav Pharmacol; 2003 Dec; 14(8):641-7. PubMed ID: 14665981
[TBL] [Abstract][Full Text] [Related]
16. Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats.
Craft RM; McNiel DM
Pharmacol Biochem Behav; 2003 Apr; 75(1):235-45. PubMed ID: 12759132
[TBL] [Abstract][Full Text] [Related]
17. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
Morgan D; Picker MJ
Psychopharmacology (Berl); 1998 Nov; 140(1):20-8. PubMed ID: 9862398
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
Picker MJ; Cook CD
Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
[TBL] [Abstract][Full Text] [Related]
19. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
Picker MJ; Benyas S; Horwitz JA; Thompson K; Mathewson C; Smith MA
J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
[TBL] [Abstract][Full Text] [Related]
20. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
Picker MJ; Dykstra LA
J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
